LINK . SPRINGER . COM {
}
Title:
Effects of the cardioselective KATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and in anesthetized rats during ischemia and reperfusion | Naunyn-Schmiedeberg's Archives of Pharmacology
Description:
It has been argued that activation of KATP channels in the sarcolemmal membrane of heart muscle cells during ischemia provides an endogenous cardioprotective mechanism. In order to test whether the novel cardioselective KATP channel blocker HMR 1098 affects cardiac function during ischemia, experiments were performed in rat hearts during ischemia and reperfusion. Isolated perfused working rat hearts were subjected to 30 min of low-flow ischemia in which the coronary flow was reduced to 10% of its control value, followed by 30-min reperfusion. In the first set of experiments the hearts were electrically paced at 5 Hz throughout the entire protocol. At the end of the 30-min ischemic period the aortic flow had fallen to 44±2% (n=8) of its nonischemic value in vehicle-treated hearts, whereas in the presence of 0.3 µmol/l and 3 µmol/l HMR 1098 it had fallen to 29±7% (n=5, not significant) and 8±2% (n=12, P<0.05), respectively. Glibenclamide (3 µmol/l) reduced the aortic flow to 9.5±7% (n=4, P<0.05). In control hearts the QT interval in the electrocardiogram shortened from 63±6 ms to 36±4 ms (n=10, P<0.05) within 4–6 min of low-flow ischemia. This shortening was completely prevented by 3 µmol/l HMR 1098 (60±5 ms before ischemia, 67±6 ms during ischemia, n=9, not significant). When rat hearts were not paced, the heart rate fell spontaneously during ischemia, and HMR 1098 (3 µmol/l) caused only a slight, statistically non-significant reduction in aortic flow during the ischemic period. In order to investigate whether HMR 1098 shows cardiodepressant effects in a more pathophysiological model, the left descending coronary artery was occluded for 30 min followed by reperfusion for 60 min in anesthetized rats. Treatment with HMR 1098 (10 mg/kg i.v.) had no statistically significant effects on mean arterial blood pressure and heart rate during the control, ischemia and reperfusion periods. At the end of the reperfusion period, aortic blood flow was slightly reduced by HMR 1098, without reaching statistical significance (two-way analysis of ANOVA, P=0.15). Myocardial infarct size as a percentage of area at risk was not affected by HMR 1098 (vehicle: 75±3%, HMR 1098: 72±2%, n=7 in each group). In conclusion, cardiodepressant effects of HMR 1098 were observed only in isolated perfused working rat hearts which were continuously paced during global low-flow ischemia. In the model of anesthetized rats subjected to regional ischemia, HMR 1098 had no significant effect on cardiac function or infarct size.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Health & Fitness
- Social Networks
- TV
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
We can't tell how the site generates income.
While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.
Keywords {🔍}
hmr, ischemia, article, hearts, reperfusion, rat, heart, min, privacy, cookies, function, content, effects, katp, rats, channels, flow, µmoll, information, publish, search, channel, cardiac, isolated, perfused, working, anesthetized, aortic, significant, access, data, log, journal, research, cardioselective, blocker, gögelein, ruetten, albus, lowflow, reduced, control, paced, period, potassium, discover, springer, optional, analysis, personal,
Topics {✒️}
month download article/chapter dg cardiovascular diseases pore-domain potassium katp channels article naunyn-schmiedeberg' global low-flow ischemia myocardial infarct size july 2001 volume 364 privacy choices/manage cookies heart muscle cells heart failure full article pdf endogenous cardioprotective mechanism arterial blood pressure reaching statistical significance murine disease models related subjects conditions privacy policy rat hearts vehicle-treated hearts channels heart rate low-flow ischemia accepting optional cookies european economic area aortic blood flow anesthetized rats subjected check access instant access journal finder publish article gögelein main content log cardiac function heinz gögelein statistically significant effects 30-min ischemic period anesthetized rats article log information privacy policy personal data coronary flow cardiodepressant effects books a article cite optional cookies manage preferences infarct size aortic flow ischemic period
Schema {🗺️}
WebPage:
mainEntity:
headline:Effects of the cardioselective KATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and in anesthetized rats during ischemia and reperfusion
description: It has been argued that activation of KATP channels in the sarcolemmal membrane of heart muscle cells during ischemia provides an endogenous cardioprotective mechanism. In order to test whether the novel cardioselective KATP channel blocker HMR 1098 affects cardiac function during ischemia, experiments were performed in rat hearts during ischemia and reperfusion. Isolated perfused working rat hearts were subjected to 30 min of low-flow ischemia in which the coronary flow was reduced to 10% of its control value, followed by 30-min reperfusion. In the first set of experiments the hearts were electrically paced at 5 Hz throughout the entire protocol. At the end of the 30-min ischemic period the aortic flow had fallen to 44±2% (n=8) of its nonischemic value in vehicle-treated hearts, whereas in the presence of 0.3 µmol/l and 3 µmol/l HMR 1098 it had fallen to 29±7% (n=5, not significant) and 8±2% (n=12, P<0.05), respectively. Glibenclamide (3 µmol/l) reduced the aortic flow to 9.5±7% (n=4, P<0.05). In control hearts the QT interval in the electrocardiogram shortened from 63±6 ms to 36±4 ms (n=10, P<0.05) within 4–6 min of low-flow ischemia. This shortening was completely prevented by 3 µmol/l HMR 1098 (60±5 ms before ischemia, 67±6 ms during ischemia, n=9, not significant). When rat hearts were not paced, the heart rate fell spontaneously during ischemia, and HMR 1098 (3 µmol/l) caused only a slight, statistically non-significant reduction in aortic flow during the ischemic period. In order to investigate whether HMR 1098 shows cardiodepressant effects in a more pathophysiological model, the left descending coronary artery was occluded for 30 min followed by reperfusion for 60 min in anesthetized rats. Treatment with HMR 1098 (10 mg/kg i.v.) had no statistically significant effects on mean arterial blood pressure and heart rate during the control, ischemia and reperfusion periods. At the end of the reperfusion period, aortic blood flow was slightly reduced by HMR 1098, without reaching statistical significance (two-way analysis of ANOVA, P=0.15). Myocardial infarct size as a percentage of area at risk was not affected by HMR 1098 (vehicle: 75±3%, HMR 1098: 72±2%, n=7 in each group). In conclusion, cardiodepressant effects of HMR 1098 were observed only in isolated perfused working rat hearts which were continuously paced during global low-flow ischemia. In the model of anesthetized rats subjected to regional ischemia, HMR 1098 had no significant effect on cardiac function or infarct size.
datePublished:
dateModified:
pageStart:33
pageEnd:41
sameAs:https://doi.org/10.1007/s002100000391
keywords:
KATP channel Heart Ischemia HMR 1098 HMR 1883 Rat Myocardial contractility
Pharmacology/Toxicology
Neurosciences
image:
isPartOf:
name:Naunyn-Schmiedeberg's Archives of Pharmacology
issn:
1432-1912
0028-1298
volumeNumber:364
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Heinz Gögelein
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Hartmut Ruetten
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Udo Albus
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Heinrich C. Englert
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Andreas E. Busch
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Effects of the cardioselective KATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and in anesthetized rats during ischemia and reperfusion
description: It has been argued that activation of KATP channels in the sarcolemmal membrane of heart muscle cells during ischemia provides an endogenous cardioprotective mechanism. In order to test whether the novel cardioselective KATP channel blocker HMR 1098 affects cardiac function during ischemia, experiments were performed in rat hearts during ischemia and reperfusion. Isolated perfused working rat hearts were subjected to 30 min of low-flow ischemia in which the coronary flow was reduced to 10% of its control value, followed by 30-min reperfusion. In the first set of experiments the hearts were electrically paced at 5 Hz throughout the entire protocol. At the end of the 30-min ischemic period the aortic flow had fallen to 44±2% (n=8) of its nonischemic value in vehicle-treated hearts, whereas in the presence of 0.3 µmol/l and 3 µmol/l HMR 1098 it had fallen to 29±7% (n=5, not significant) and 8±2% (n=12, P<0.05), respectively. Glibenclamide (3 µmol/l) reduced the aortic flow to 9.5±7% (n=4, P<0.05). In control hearts the QT interval in the electrocardiogram shortened from 63±6 ms to 36±4 ms (n=10, P<0.05) within 4–6 min of low-flow ischemia. This shortening was completely prevented by 3 µmol/l HMR 1098 (60±5 ms before ischemia, 67±6 ms during ischemia, n=9, not significant). When rat hearts were not paced, the heart rate fell spontaneously during ischemia, and HMR 1098 (3 µmol/l) caused only a slight, statistically non-significant reduction in aortic flow during the ischemic period. In order to investigate whether HMR 1098 shows cardiodepressant effects in a more pathophysiological model, the left descending coronary artery was occluded for 30 min followed by reperfusion for 60 min in anesthetized rats. Treatment with HMR 1098 (10 mg/kg i.v.) had no statistically significant effects on mean arterial blood pressure and heart rate during the control, ischemia and reperfusion periods. At the end of the reperfusion period, aortic blood flow was slightly reduced by HMR 1098, without reaching statistical significance (two-way analysis of ANOVA, P=0.15). Myocardial infarct size as a percentage of area at risk was not affected by HMR 1098 (vehicle: 75±3%, HMR 1098: 72±2%, n=7 in each group). In conclusion, cardiodepressant effects of HMR 1098 were observed only in isolated perfused working rat hearts which were continuously paced during global low-flow ischemia. In the model of anesthetized rats subjected to regional ischemia, HMR 1098 had no significant effect on cardiac function or infarct size.
datePublished:
dateModified:
pageStart:33
pageEnd:41
sameAs:https://doi.org/10.1007/s002100000391
keywords:
KATP channel Heart Ischemia HMR 1098 HMR 1883 Rat Myocardial contractility
Pharmacology/Toxicology
Neurosciences
image:
isPartOf:
name:Naunyn-Schmiedeberg's Archives of Pharmacology
issn:
1432-1912
0028-1298
volumeNumber:364
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Heinz Gögelein
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Hartmut Ruetten
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Udo Albus
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Heinrich C. Englert
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Andreas E. Busch
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Naunyn-Schmiedeberg's Archives of Pharmacology
issn:
1432-1912
0028-1298
volumeNumber:364
Organization:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Heinz Gögelein
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
name:Hartmut Ruetten
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
name:Udo Albus
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
name:Heinrich C. Englert
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
name:Andreas E. Busch
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
PostalAddress:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(33)
- Find out how much https://www.springernature.com/gp/authors earns monthly
- Income figures for https://link.springernature.com/home/
- Check the income stats for https://order.springer.com/public/cart
- What is the monthly revenue of https://submission.nature.com/new-submission/210/3?
- What's the financial gain of https://www.springernature.com/gp/librarians/licensing/agc/journals?
- Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Heinz%20G%C3%B6gelein
- Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Heinz%20G%C3%B6gelein%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hartmut%20Ruetten generate monthly?
- How profitable is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hartmut%20Ruetten%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Udo%20Albus
- Find out how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Udo%20Albus%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earns monthly
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Heinrich%20C.%20Englert make?
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Heinrich%20C.%20Englert%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andreas%20E.%20Busch?
- How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andreas%20E.%20Busch%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- Financial intake of https://s100.copyright.com/AppDispatchServlet?title=Effects%20of%20the%20cardioselective%20KATP%20channel%20blocker%20HMR%201098%20on%20cardiac%20function%20in%20isolated%20perfused%20working%20rat%20hearts%20and%20in%20anesthetized%20rats%20during%20ischemia%20and%20reperfusion&author=Heinz%20G%C3%B6gelein%20et%20al&contentID=10.1007%2Fs002100000391©right=Springer-Verlag&publication=0028-1298&publicationDate=2001-07&publisherName=SpringerNature&orderBeanReset=true
- How profitable is https://citation-needed.springer.com/v2/references/10.1007/s002100000391?format=refman&flavour=citation?
- How much does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral make?
- Learn about the earnings of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
- What is the monthly revenue of https://www.springernature.com/gp/products?
- Check the income stats for https://www.springernature.com/gp/librarians
- What are the total earnings of https://www.springernature.com/gp/societies?
- What's the income of https://www.springernature.com/gp/partners?
- Monthly income for https://www.springer.com/
- How much income is https://www.nature.com/ earning monthly?
- What's the profit of https://www.biomedcentral.com/?
- How much revenue does https://www.palgrave.com/ produce monthly?
- How much does https://www.apress.com/ pull in monthly?
- How much does https://www.springernature.com/gp/legal/ccpa generate monthly?
- What is the earnings of https://www.springernature.com/gp/info/accessibility?
- Income figures for https://support.springernature.com/en/support/home
- What are the total earnings of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations?
- What's the income generated by https://www.springernature.com/ each month?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref